HBV感染不同阶段血清HBV大表面蛋白的预测价值及慢性乙型肝

StephenW

Clin Chim Acta. 2018 Feb 14. pii: S0009-8981(18)30076-7. doi: 10.1016/j.cca.2018.02.015. [Epub ahead of print]
Prediction value of serum HBV large surface protein in different phases of HBV infection and virological response of chronic hepatitis B patients.Liu C1, Wu W1, Shang H1, Lin S1, Xun Z1, Huang E1, Lin J1, Yang B1, Ou Q2.
Author information
1Department of Laboratory Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian Province, China; Gene Diagnostic Laboratory, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian Province, China.2Department of Laboratory Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian Province, China; Gene Diagnostic Laboratory, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian Province, China. Electronic address: [email protected].

AbstractBACKGROUND: Serum HBV large surface protein (HBV-LP) is an envelope protein that has a close relationship with HBV DNA level. This study is to explore the prediction value of HBV-LP in different phase of HBV infection and during antiviral therapy in chronic hepatitis B (CHB) patients.
METHODS: A retrospective study was conducted in 2033 individuals, which included 1677 HBV infected patients in different phases and 356 healthy controls. HBV-LP, HBV serum markers and HBV DNA were detected by ELISA, CMIA and qRT-PCR, respectively. 85 CHB patients receiving PegIFNα or ETV were divided into virological response (VR) and partial virological response (PVR). The dynamic changes of HBV DNA and HBV-LP were observed.
RESULTS: The level of HBV-LP in 2033 individuals was shown as: HBeAg-positive hepatitis > HBeAg-positive infection > HBeAg-negative hepatitis > HBeAg-negative infection > healthy controls. HBV-LP was positive in all patients whose HBV DNA > 1.0E + 06 IU/ml. When HBsAg was <0.05 IU/ml or >1000 IU/ml, HBV DNAs were all negative if HBV-LP < 1.0 S/CO. When HBsAg was between 0.05 IU/ml and 1000 IU/ml, the consistency of HBV-LP with HBV DNA was 100% in case of HBV-LP > 4.0 S/CO in HBeAg-positive patients and HBV-LP > 2.0 S/CO in HBeAg-negative ones. During antiviral therapy, baseline HBV-LP was lower in VR patients than that in PVR patients. The optimal cut-off points to predict VR by baseline HBV-LP were 32.35 and 28.6 S/CO for HBeAg-positive and HBeAg-negative hepatitis patients, respectively.
CONCLUSIONS: HBV-LP may be a useful marker for distinguishing the different phases of HBV infection. Moreover, baseline HBV-LP level can be used for predicting VR of CHB patients.

Copyright © 2017. Published by Elsevier B.V.

KEYWORDS: Antiviral therapy; HBV DNA; Hepatitis B virus; Large surface protein; Quantitative HBsAg

PMID:29453971DOI:10.1016/j.cca.2018.02.015

StephenW

Clin Chim Acta。 2018年2月14日。pii：S0009-8981（18）30076-7。 doi：10.1016 / j.cca.2018.02.015。 [电子版提前打印]
HBV感染不同阶段血清HBV大表面蛋白的预测价值及慢性乙型肝炎患者的病毒学应答。
Liu C1，Wu W1，Shang H1，Lin S1，Xun Z1，Huang E1，Lin J1，Yang B1，Ou Q2。
作者信息

1
    福建医科大学附属第一医院检验科，福建福州;福建医科大学第一附属医院基因诊断实验室，福建福州。
2
    福建医科大学附属第一医院检验科，福建福州;福建医科大学第一附属医院基因诊断实验室，福建福州。电子地址：[email protected]。

抽象
背景：

血清HBV大表面蛋白（HBV-LP）是与HBV DNA水平密切相关的包膜蛋白。本研究旨在探讨HBV-LP在慢性乙型肝炎（CHB）患者HBV感染不同阶段和抗病毒治疗期间的预测价值。
方法：

2033名个体进行了回顾性研究，其中包括1677名不同阶段的HBV感染患者和356名健康对照。 HBV-LP，HBV血清标志物和HBV DNA分别通过ELISA，CMIA和qRT-PCR检测。将85名接受PegIFNα或ETV的CHB患者分为病毒学应答（VR）和部分病毒应答（PVR）。观察HBV DNA和HBV-LP的动态变化。
结果：

2033例HBV-LP水平表现为：HBeAg阳性肝炎> HBeAg阳性感染> HBeAg阴性肝炎> HBeAg阴性感染>健康对照组。所有HBV DNA> 1.0E + 06IU / ml的患者HBV-LP阳性。当HBsAg <0.05IU / ml或> 1000IU / ml时，HBV-LP <1.0S / CO时HBV DNA均为阴性。当HBsAg介于0.05IU / ml和1000IU / ml之间时，HBeAg阳性患者HBV-LP> 4.0S / CO时HBV-LP与HBV DNA的一致性为100％，HBV-LP> 2.0S / CO在HBeAg阴性者中的表达。在抗病毒治疗期间，VR患者的基线HBV-LP低于PVR患者。基线HBV-LP预测VR的最佳截点分别为HBeAg阳性和HBeAg阴性肝炎患者的32.35和28.6S / CO。
结论：

HBV-LP可能是区分HBV感染不同阶段的有用指标。此外，基线HBV-LP水平可用于预测CHB患者的VR。

版权©2017.由Elsevier B.V.出版
关键词：

抗病毒治疗; HBV DNA;乙型肝炎病毒;大面积蛋白质;定量HBsAg

结论：
    29453971
DOI：
    10.1016 / j.cca.2018.02.015